Comparative Pharmacology
Head-to-head clinical analysis: STRONTIUM CHLORIDE SR 89 versus THALLOUS CHLORIDE TL 201.
Peer-Reviewed Evidence
Head-to-head clinical analysis: STRONTIUM CHLORIDE SR 89 versus THALLOUS CHLORIDE TL 201.
STRONTIUM CHLORIDE SR-89 vs THALLOUS CHLORIDE TL 201
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Strontium-89 is a calcium mimetic that localizes to bone, particularly areas of increased osteoblastic activity, emitting beta radiation that causes DNA damage and cell death in metastatic tumor cells.
Thallous chloride Tl-201 is a potassium analog that is taken up by viable myocardial cells via the Na+/K+ ATPase pump. Its distribution reflects regional myocardial blood flow and cell viability. In areas of ischemia or infarction, uptake is reduced, creating a perusion defect.
148 MBq (4 mCi) intravenously over 1-2 minutes, single dose. Repeat after 3-6 months if needed.
111-148 MBq (3-4 mCi) intravenous injection for myocardial perfusion imaging; imaging begins 5-10 minutes post-injection.
None Documented
None Documented
Terminal elimination half-life: 50.5 days (range 33–65 days). Reflects slow clearance from bone; clinical effect persists due to long skeletal retention.
Terminal elimination half-life: approximately 73 hours. Clinical context: The long half-life allows for delayed imaging (e.g., redistribution imaging for thallium-201 myocardial perfusion scans).
Primarily renal (urinary) excretion; approximately 50-80% of absorbed dose eliminated via urine over 7 days. Fecal elimination is negligible (<5%).
Renal: approximately 70% over 10 days; fecal: less than 30% over 10 days.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical